Effects of carvedilol treatment in dogs with chronic mitral valvular disease

Journal of Veterinary Internal Medicine

Volumn 21, Issue 5, 2007, Pages 996-1001

  Marcondes Santos, Mario ^a,b   Tarasoutchi, Flavio ^a   Mansur, Antonio P ^a   Strunz, Célia M C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Sena Madureira Veterinary Hospital   (Brazil)

Author keywords

Beta blocker; Cardiology; Dog; Heart failure; Mitral valve; Quality of life

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; NORADRENALIN; PROPANOLAMINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BLOOD PRESSURE; DOG; DOG DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; FEMALE; MALE; MITRAL VALVE REGURGITATION; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARBAZOLES; DOG DISEASES; DOGS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; MALE; MITRAL VALVE INSUFFICIENCY; NOREPINEPHRINE; PROPANOLAMINES; QUALITY OF LIFE; QUESTIONNAIRES; STATISTICS, NONPARAMETRIC;

EID: 34848854822     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2007.tb03055.x     Document Type: Article

References (46)

1. Levine TB, Francis GS, Goldsmith SR, et al. Activity of sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-1666.
2. Ware WA, Lund DD, Subieta AR, et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990;197:1475-1481.
3. Sisson D, Kittleson MD. Management of heart failure: principles of treatment, therapeutics strategies and pharmacology. In: Fox PR, Sisson D, Moïse NS, eds. Textbook of Canine and Feline Cardiology-Principles and Clinical Practice, 2nd ed. Philadelphia: WB Saunders; 1999:216-250.
4. Ishise H, Asanoi H, Ishizaka S, et al. Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure. J Appl Physiol 1998;84: 1234-1241.
5. Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 2004;34:1105-1126.
6. Dorn GW. Adrenergic pathways and left ventricular remodeling. J Card Fail 2002;8(Suppl):S370-S373.
7. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-243.
8. Francis GS, Goldsmith SR, Cohn JN. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982;104:725-731.
9. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med 1984;311:850-851.
10. Ross RD, Daniels SR, Schwartz DC, et al. Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 1987;59:911-914.
11. Rector TS, Olivari MT, Levine TB, et al. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987;114:148-152.
12. Abraham WT, Hensen J, Schrier RW. Elevated plasma noradrenaline concentrations in patients with low-output cardiac failure: dependence on increased noradrenaline secretion rates. Clin Sci (Lond) 1990;79:429-435.
13. Patel MB, Stewart JM, Loud AV, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991;84:2091-2100.
14. Sato N, Vatner SF, Shen YT, et al. Effects on cardiac denervation on development of heart failure and catecholamine desensitization. Circulation 1997;95:2130-2140.
15. Houle MS, Billman GE. Low-frequency component of heart rate variability spectrum: a poor marker of sympathetic activity. Am J Physiol 1999;276:H215-H223.
16. Ohtsuka S, Suzuki S, Ishikawa K, et al. Norepinephrine release is increased in the hibernating heart, studied in a chronic model of myocardial hibernation. J Cardiovasc Pharmacol 2000;36(Suppl 2):S35-S41.
17. Stewart JM, Patel MB, Wang J, et al. Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol 1992;262:H331-H339.
18. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
19. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
20. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L.
21. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-697.
22. Sawangkoon S, Miyamoto M, Nakayama T, Hamlin RL. Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. Am J Vet Res 2000;61:57-60.
23. Abbott JA, Broadstone RV, Ward DL, Pyle RL. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. Am J Vet Res 2005;66:637-641.
24. Arsenault WG, Boothe DM, Gordon SG, et al. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. Am J Vet Res 2005;66:2172-2176.
25. Gordon SG, Arsenault WG, Longnecker M, et al. Pharmacodynamics of carvedilol in conscious, healthy dogs. J Vet Intern Med 2006;20:297-304.
26. Uechi M, Sasaki T, Ueno K, et al. Cardiovascular and renal effects of carvedilol in dogs with heart failure. J Vet Med Sci. 2002;64:469-475.
27. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-2648.
28. Nemoto S, Hamawaki M, De Freitas G, Carabello B. A. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol 2002;40:149-154.
29. Tallaj J, Wei CC, Hankes GH, et al. Beta 1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation. Circulation 2003;108:225-230.
30. Häggström J, Kvart C, Pedersen HD. Acquired valvular heart disease. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. St. Louis: Elsevier Saunders; 2005:1022-1036.
31. Fuji Y, Wakao Y. Spectral analysis of heart rate variability in dogs with mild mitral regurgitation. Am J Vet Res 2003;64:145-148.
32. Marcondes Santos M, Strunz CM, Larsson MH. Correlation between activation of the sympathetic nervous system estimated by plasma concentrations of norepinephrine and Doppler echocardiographic variables in dogs with acquired heart disease. Am J Vet Res 2006;67:1163-1168.
33. Rush EJ, Freeman LM, Hiler C, Brown DJ. Use of metoprolol in dogs with acquired cardiac disease. J Vet Cardiol 2002;4:23-28.
34. Freeman LM, Rush JE, Farabaugh AE, Must A. Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease. J Am Vet Med Assoc 2005;226:1864-1868.
35. Bühler HU, da Prada M, Haefely W, et al. Plasma adrenaline, noradrenaline and dopamine in man and different animal species. J Physiol 1978;276:311-320.
36. Yui Y, Fujita T, Yamamoto T, et al. Liquid-chromatographic determination of norepinephrine and epinephrine in human plasma. Clin Chem 1980;26:194-196.
37. Krstulovic AM. Investigations of catecholamine metabolism using high-performance liquid chromatography. J Chromatogr 1982;229:1-34.
38. Davies CL, Molyneux SG. Routine determination of plasma catecholamines using reversed-phase ion-pair high-performance liquid chromatography with electrochemical detection. J Chromatogr 1982;231:41-51.
39. Bouloux P, Perrett D, Besser GM. Methodological considerations in the determination of plasma catecholamines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1985;22:194-203.
40. Chetboul V, Tidholm A, Nicolle A, et al. Effects of animal position and number of repeated measurements on selected two-dimensional and M-mode echocardiographic variables in healthy dogs. J Am Vet Assoc 2005;227:743-747.
41. Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. J Vet Intern Med 1993;7:247-252.
42. Boon JA. The echocardiographic examination. In Boon JA, ed. Manual of Veterinary Echocardiography. Baltimore: Williams & Wilkins; 1998:151-260.
43. Brown DJ, Rush JE, MacGregor J, et al. M-mode echocardiographic ratio indices in normal dogs, cats, and horses: a novel quantitative method. J Vet Intern Med 2003;17:653-662.
44. Remillard RL, Ross JN, Eddy JB. Variance of indirect blood pressure measurements and prevalence of hypertension in clinically normal dogs. Am J Vet Res 1991;52:561-565.
45. Stepien RL, Rapoport GS. Clinical comparison of three methods to measure blood pressure in nonsedated dogs. J Am Vet Med Assoc 1999;215:1623-1628.
46. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;45:232-258.